Interferon alfa-associated anterior ischemic optic neuropathy

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To report a possible association between interferon alfa therapy and anterior ischemic optic neuropathy (AION). Design: Database study and review of the literature. Participants: Thirty-six case reports from spontaneous reporting systems and the literature. Methods: Case reports from a review of the literature were combined with spontaneous reports from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration looking for reports on interferon therapy associated with optic neuropathy. Main Outcome Measures: Data from the spontaneous reports include the type of interferon, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of ADR, concomitant drugs, systemic disease, and dechallenge and rechallenge data. Results: Thirty-six case reports of AION are described in association with interferon alfa therapy. The average age of subjects was 54.5 years; 26 were male and 10 were female. The median duration of therapy to onset of AION was 4.5 months, with 50% of subjects having some form of permanent vision loss. Anterior ischemic optic neuropathy was bilateral in 67% of subjects. There are 3 positive rechallenge case reports. Conclusions: Interferon alfas association with AION can be classified as "possible" using the World Health Organization classification system. If optic neuropathy is suspected, rapid cessation of interferon therapy may portend a better prognosis because multiple case reports indicate visual defects may be permanent if this possible ADR remains unrecognized. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)408-411
Number of pages4
JournalOphthalmology
Volume118
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Ischemic Optic Neuropathy
Interferon-alpha
Drug-Related Side Effects and Adverse Reactions
Interferons
Optic Nerve Diseases
Disclosure
Therapeutics
United States Food and Drug Administration
Pharmaceutical Preparations
Registries
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Interferon alfa-associated anterior ischemic optic neuropathy. / Fraunfelder, F. W.; Fraunfelder, Frederick (Fritz).

In: Ophthalmology, Vol. 118, No. 2, 02.2011, p. 408-411.

Research output: Contribution to journalArticle

@article{80e5f0a00c9f42bda98496e0041279d3,
title = "Interferon alfa-associated anterior ischemic optic neuropathy",
abstract = "Purpose: To report a possible association between interferon alfa therapy and anterior ischemic optic neuropathy (AION). Design: Database study and review of the literature. Participants: Thirty-six case reports from spontaneous reporting systems and the literature. Methods: Case reports from a review of the literature were combined with spontaneous reports from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration looking for reports on interferon therapy associated with optic neuropathy. Main Outcome Measures: Data from the spontaneous reports include the type of interferon, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of ADR, concomitant drugs, systemic disease, and dechallenge and rechallenge data. Results: Thirty-six case reports of AION are described in association with interferon alfa therapy. The average age of subjects was 54.5 years; 26 were male and 10 were female. The median duration of therapy to onset of AION was 4.5 months, with 50{\%} of subjects having some form of permanent vision loss. Anterior ischemic optic neuropathy was bilateral in 67{\%} of subjects. There are 3 positive rechallenge case reports. Conclusions: Interferon alfas association with AION can be classified as {"}possible{"} using the World Health Organization classification system. If optic neuropathy is suspected, rapid cessation of interferon therapy may portend a better prognosis because multiple case reports indicate visual defects may be permanent if this possible ADR remains unrecognized. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Fraunfelder, {F. W.} and Fraunfelder, {Frederick (Fritz)}",
year = "2011",
month = "2",
doi = "10.1016/j.ophtha.2010.03.063",
language = "English (US)",
volume = "118",
pages = "408--411",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Interferon alfa-associated anterior ischemic optic neuropathy

AU - Fraunfelder, F. W.

AU - Fraunfelder, Frederick (Fritz)

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: To report a possible association between interferon alfa therapy and anterior ischemic optic neuropathy (AION). Design: Database study and review of the literature. Participants: Thirty-six case reports from spontaneous reporting systems and the literature. Methods: Case reports from a review of the literature were combined with spontaneous reports from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration looking for reports on interferon therapy associated with optic neuropathy. Main Outcome Measures: Data from the spontaneous reports include the type of interferon, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of ADR, concomitant drugs, systemic disease, and dechallenge and rechallenge data. Results: Thirty-six case reports of AION are described in association with interferon alfa therapy. The average age of subjects was 54.5 years; 26 were male and 10 were female. The median duration of therapy to onset of AION was 4.5 months, with 50% of subjects having some form of permanent vision loss. Anterior ischemic optic neuropathy was bilateral in 67% of subjects. There are 3 positive rechallenge case reports. Conclusions: Interferon alfas association with AION can be classified as "possible" using the World Health Organization classification system. If optic neuropathy is suspected, rapid cessation of interferon therapy may portend a better prognosis because multiple case reports indicate visual defects may be permanent if this possible ADR remains unrecognized. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Purpose: To report a possible association between interferon alfa therapy and anterior ischemic optic neuropathy (AION). Design: Database study and review of the literature. Participants: Thirty-six case reports from spontaneous reporting systems and the literature. Methods: Case reports from a review of the literature were combined with spontaneous reports from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration looking for reports on interferon therapy associated with optic neuropathy. Main Outcome Measures: Data from the spontaneous reports include the type of interferon, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of ADR, concomitant drugs, systemic disease, and dechallenge and rechallenge data. Results: Thirty-six case reports of AION are described in association with interferon alfa therapy. The average age of subjects was 54.5 years; 26 were male and 10 were female. The median duration of therapy to onset of AION was 4.5 months, with 50% of subjects having some form of permanent vision loss. Anterior ischemic optic neuropathy was bilateral in 67% of subjects. There are 3 positive rechallenge case reports. Conclusions: Interferon alfas association with AION can be classified as "possible" using the World Health Organization classification system. If optic neuropathy is suspected, rapid cessation of interferon therapy may portend a better prognosis because multiple case reports indicate visual defects may be permanent if this possible ADR remains unrecognized. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=79551530645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551530645&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.03.063

DO - 10.1016/j.ophtha.2010.03.063

M3 - Article

C2 - 20630599

AN - SCOPUS:79551530645

VL - 118

SP - 408

EP - 411

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 2

ER -